SHR-1701 clinical trials
Also written SHR-1701 and Retlirafusp alfa.
How each study uses SHR-1701 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SHR-1701 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
59 studies that test it; most in 2026 (31)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 31 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 43
Jiangsu HengRui Medicine Co., Ltd. (10) · Fudan University (6) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (5) · Tianjin Medical University Cancer Institute and Hospital (3) · Tang-Du Hospital (3) · Harbin Medical University (2) · Henan Cancer Hospital (2) · Peking University Cancer Hospital & Institute (2)
Often tested with
Tested in the same studies.
Apatinib (8) · Adebrelimab (6) · Zeprumetostat (6) · Trastuzumab rezetecan (4) · Famitinib (4) · Fluzoparib (2) · Bevacizumab (2) · CAPOX Regimen (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7
Studies that test SHR-1701.
- Mar 2027Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)Phase 2 · Tianjin Medical University Cancer Institute and Hospital
- Apr 2027Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and EfficacyNot applicable · Tianjin Medical University Cancer Institute and Hospital
- May 2027Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCCPhase 2 · Tang-Du Hospital
- Jul 2027Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung CancerPhase 1/2 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Aug 2027Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic CancerPhase 2 · The First Affiliated Hospital of Zhengzhou University
- Sep 2027Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.Phase 2 · Fudan University
- Sep 2027SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After ImmunotherapyPhase 2 · Zhigang Li
Studies
Open first, then newest update. How each study uses SHR-1701 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 59
- A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal MelanomaRecruitingPhase 2Sun Yat-sen UniversityNCT07934927Written as Retlirafusp Alfa Injection
- Retlirafusp Alfa or Adebrelimab Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Qun ZhaoNCT07924332Written as Retlirafusp Alfa Plus Chemotherapy
- GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDACRecruitingPhase 1/2West China HospitalNCT07802184Written as SHR-1701
- Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal MetastasisNot yet recruitingPhase 2Anhui Provincial Cancer HospitalNCT07904442Written as Retlirafusp alfa + nab-paclitaxel + apatinib
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07847710Written as Retlirafusp alfa
- Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingPhase 2Fudan UniversityNCT07874425Written as Retlirafusp alfa
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNot applicableNanjing Tianyinshan HospitalNCT06893887Written as Retlirafusp alfa
- Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLMRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07728019Written as Retlirafusp alfa Injection
- Trastuzumab Combined With Retlirafusp Alfa in Treating HER2(Human Epidermal Growth Factor Receptor 2) 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy FailureNot yet recruitingPhase 2Henan Cancer HospitalNCT07817654Written as Trastuzumab Rezetecan+Retlirafusp alfa
- Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic CancerNot yet recruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07814859Written as Retlirafusp alfa Injection
- Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited MetastasesNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07815288Written as Retlirafusp alfa Combined with Targeted Therapy and Chemotherapy
- Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07802288Written as Trastuzumab Rezetecan + Retlirafusp alfa + CAPOX
- Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic CancerNot yet recruitingPhase 2Tang-Du HospitalNCT07773363Written as Retlirafusp Alfa
- An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual ImagingNot yet recruitingPhase 2Tan LijieNCT07770672Written as Retlirafusp Alfa Plus Chemotherapy
- Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast CancerNot yet recruitingPhase 2Harbin Medical UniversityNCT07752550Written as Retlirafusp alfa+Nab-paclitaxel:
- SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07749859Written as Retlirafusp alfa Injection, apatinib
- Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Tang-Du HospitalNCT07709767Written as Retlirafusp Alfa
- SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric CancerRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07464756Written as SHR-1701
- Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric CancerRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07689851Written as SHR-1701
- Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver MetastasesNot yet recruitingPhase 3Peking UniversityNCT07677293Written as Retlirafusp alfa Injection
See all 59 studies that test SHR-1701 →
Given beside what is tested · 6 — SHR-1701 is usual care or a partner of the new treatment
- PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07294664Written as SHR1701
- SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal MetastasisRecruitingPhase 2Ruijin HospitalNCT07384234Written as SHR-1701
- SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung CancerNot yet recruitingPhase 2Fudan UniversityNCT07619911Written as SHR-1701 consolidation therapy
- Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07102901Written as SHR-1701 Injection
- Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic CancerActive, not recruitingPhase 2The First Hospital of Jilin UniversityNCT07806110Written as SHR-1701
- A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid TumorsStatus unknownPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT04679038Written as SHR-1701
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDACNov 9, 2026NCT07802184
Newly registered3
- A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal MelanomaNov 13, 2026NCT07934927
- Retlirafusp Alfa or Adebrelimab Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric or Gastroesophageal Junction AdenocarcinomaNov 9, 2026NCT07924332
- Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal MetastasisOct 29, 2026NCT07904442